ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02561962
Recruitment Status : Recruiting
First Posted : September 28, 2015
Last Update Posted : December 21, 2017
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: AMG 224 Phase 1

Detailed Description:
This is a first in human phase 1 multicenter open label study to evaluate the safety and tolerability of AMG 224 in subjects with relapsed or refractory multiple myeloma. The study will be conducted in 2 parts. Part 1 is the dose-exploration and part 2 is the dose-expansion. Study medication will be administered once every 3 weeks by IV.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
Actual Study Start Date : November 20, 2015
Estimated Primary Completion Date : September 17, 2018
Estimated Study Completion Date : March 13, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Dose Exploration Drug: AMG 224
AMG 224 will be given on Day 1 once every 3 weeks with dose ranging from 30 mg to 300 mg.




Primary Outcome Measures :
  1. Safety: Incidence of dose limiting toxicities (DLTs), treatment-related, treatment-emergent [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Pathologically documented,multiple myeloma relapsed or refractory progressive disease after at least 3 lines of therapy for multiple myeloma.

Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g. bortezomib) and immunomodulatory drugs (e.g. lenalidomide).

  • Willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines).
  • Measurable disease per the IMWG response criteria
  • Hematological function, as follows, without transfusion support:
  • Absolute neutrophil count ≥ 1.0 X 10 9/L,
  • Platelet count ≥ 75 X 109/L (in patients with < 50% of bone marrow nucleated cells were plasma cells) or ≥ 50 X 109/L (in patients with ≥ 50% of bone marrow nucleated cells were plasma cells) without transfusion or growth factor support
  • Hemoglobin > 8 g/dL (> 80 g/L)
  • Adequate renal and hepatic function
  • Left ventricular ejection fraction (LVEF) > 50%

Exclusion Criteria:

  • Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study
  • Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days prior to study day 1
  • Multiple myeloma with IgM subtype
  • Glucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to study day
  • Autologous stem cell transplant less than 90 days prior to study day 1
  • POEMS syndrome, Plasma cell leukemia, Waldenstrom's macroglobulinemia or Amyloidosis
  • Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II)
  • A baseline ECG QTcF > 470 msec

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02561962


Contacts
Contact: Amgen Call Center 866-572-6436 medinfo@amgen.com

Locations
United States, California
Research Site Completed
West Hollywood, California, United States, 90069
United States, Massachusetts
Research Site Recruiting
Boston, Massachusetts, United States, 02114
United States, New York
Research Site Recruiting
New York, New York, United States, 10065
United States, Texas
Research Site Recruiting
Houston, Texas, United States, 77030
Australia, Victoria
Research Site Recruiting
Prahran, Victoria, Australia, 3181
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen

Additional Information:
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT02561962     History of Changes
Other Study ID Numbers: 20130314
First Posted: September 28, 2015    Key Record Dates
Last Update Posted: December 21, 2017
Last Verified: December 2017

Keywords provided by Amgen:
Multiple Myeloma
Relapsed Multiple Myeloma
Refractory Multiple Myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases